PARP1 and neoplasm: First, the expression of BRCA1/2 genes in the tumor may be repressed by hypermethylation of gene promoter [96,97,98], or BRCA1/2 genes may display somatic mutations [99], even though the impact of these alterations on PARP inhibitors and/or platinum sensitivity remains elusive.